Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial. (30th March 2014)

• Record Type: Journal Article
• Authors: Arshad, Abdul Rehman
• Other Names: Kostner Gerhard M. Academic Editor.
• Is Part Of: Journal of lipids. Volume 2014(2014)
• Publication Date: 2014-03-30
• Subjects: Lipids -- Periodicals; Lipids; Lipids; Electronic journals; Periodicals; Periodicals; 572.57
• DOI: 10.1155/2014/875907
• Languages: English
• ISSNs: 2090-3030

Abstract

Abstract : Background . Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke. Aim . To compare lipid-lowering efficacy of rosuvastatin with atorvastatin. Methodology . This open-label randomized controlled trial was carried out at 1 Mountain Medical Battalion from September 2012 to August 2013 on patients with type 2 diabetes, hypertension, myocardial infarction, or stroke, meriting treatment with a statin. Those with secondary causes of dyslipidemia were excluded. Blood samples for estimation of serum total cholesterol, triglycerides, HDL-C, and LDL-C were collected after a 12-hour fast. Patients were randomly allocated to receive either atorvastatin 10 mg HS or rosuvastatin 5 mg HS daily. Lipid levels were rechecked after six weeks. Results . Atorvastatin was used in 63 patients and rosuvastatin in 66. There was a greater absolute and percent reduction in serum LDL-C levels with rosuvastatin as compared to atorvastatin (0.96 versus 0.54 mg/dL; P = 0.011 and 24.34 versus 13.66%; P = 0.045 ), whereas reduction in all other fractions was equal. Myalgias were seen in 5 (7.94%) patients treated with atorvastatin and 8 (12.12%) patients treated with rosuvastatin ( P : 0.432). Conclusion . Rosuvastatin produces a greater reduction in serum LDL-C levels and should therefore be preferred over atorvastatin.